Enveda Appoints Christopher K. Porter, MBA, JD as Senior Vice President, Clinical Operations

Industry Veteran with 25+ Years Leading Biopharma and CRO Operations Joins AI-Driven Drug Discovery Company as Clinical Portfolio Expands

BOULDER, Colo.--(BUSINESS WIRE)--#AI--Enveda, a biotechnology company pioneering AI-driven drug discovery from nature, today announced the appointment of Christopher K. Porter, MBA, JD as Senior Vice President, Clinical Operations. Mr. Porter brings extensive experience in clinical development strategy, operational transformation, and scaling clinical organizations across multiple therapeutic programs.

Mr. Porter joins Enveda at a pivotal inflection point as the company advances multiple clinical-stage assets and builds infrastructure to support its expanding pipeline. His appointment underscores Enveda's commitment to operational excellence and disciplined execution as it transitions from a platform company to a multi-asset clinical-stage organization.

"Christopher's track record of transforming development operations while maintaining the highest quality standards is exactly what Enveda needs at this stage of growth," said Viswa Colluru, Founder and CEO, Enveda. "His unique perspective spanning pharma, CRO, and technology sectors, combined with his proven ability to scale operations efficiently, makes him ideally suited to lead our clinical organization through this critical phase."

Most recently, Mr. Porter served as Vice President of Development Strategy and Innovation at Theravance Biopharma, where he successfully restructured development operations across three programs encompassing nine late-phase global trials. His initiatives delivered substantial efficiency gains including accelerated enrollment, reduced database lock timelines, and meaningful cost savings while maintaining rigorous quality standards. Mr. Porter also developed and executed decentralized trial strategies and established central monitoring frameworks that modernized clinical operations.

Prior to Theravance, Mr. Porter co-founded and led Clinipace Worldwide as President, COO, and General Counsel, scaling the international CRO to over 800 employees across 30 countries. His leadership spanned clinical operations, corporate development, regulatory affairs, and quality assurance. He was named to the PharmaVoice 100 in 2008 and was a 2015 finalist for the Ernst & Young Entrepreneur of the Year in the Southeast Healthcare & Life Sciences category.

"Enveda represents a rare opportunity to apply decades of clinical operations experience to a company that is genuinely differentiated in its approach to drug discovery," said Mr. Porter. "The convergence of Enveda's AI-driven platform with evolutionarily-selected compounds creates unique development opportunities, and I'm excited to build the clinical infrastructure that will translate these discoveries into innovative therapies for patients."

Mr. Porter holds a Master of Business Administration in Marketing and a Juris Doctor from the University of North Carolina at Chapel Hill, where he also earned his undergraduate degree in Journalism. He is licensed to practice law in North Carolina and currently serves as a board member of the UNC Law Institute for Innovation.

About Enveda

Enveda is a biotechnology company that learns from life’s chemistry to create better medicines faster. Enveda uses AI-powered tools to identify and characterize a wide range of molecules produced by living organisms, the vast majority of which have never been explored by science, creating a database of chemical biodiversity: the library of life. By growing, organizing, translating, and searching this unique library, Enveda learns from life’s evolved solutions to address today’s most pressing medical needs. For more information, visit enveda.com.

Investor Contact:
Soumoditya Dey
VP, Corporate Development and Investor Relations
soumoditya.dey@enveda.com

Media Contact:
KKH Advisors
Kimberly Ha
kimberly.ha@kkhadvisors.com
917-291-5744